Publications by authors named "Hanke Zheng"
Article Synopsis
- In rheumatoid arthritis, having both anticitrullinated protein antibodies (ACPA) and rheumatoid factor (RF) indicates more severe disease and can affect treatment outcomes; abatacept is a recommended biologic treatment for those who don't respond to traditional medications.
- A study tracking 296 RA patients treated with abatacept showed significant improvement in clinical disease activity over 12 months, with mean disease activity scores decreasing by up to 74% after treatment.
- Among patients who initially had high disease activity, about 71% achieved low disease activity or remission during the follow-up, and serious adverse events were reported in only 2.4% of cases, highlighting abatacept's effectiveness and safety.
Background: This study examined the efficacy of an interdisciplinary limb preservation service (LPS) in improving surgical outcomes for diabetic foot ulcer (DFU) patients compared to traditional care.
Methods: Data from January 1, 2017 to September 30, 2020 were retrospectively reviewed. An interdisciplinary LPS clinic began on August 1, 2018, coexisting with a preexisting single specialty service.
Importance: Venous leg ulcers (VLU) are the most common cause of lower extremity ulceration that commonly occur among older individuals and are characterized by a slow healing trajectory and frequent recurrence; in the United States, VLUs affect more than 600 000 people per year with an estimated cost of $3.5 billion. Clinical trial data show that early intervention with endovenous ablation substantially improves the healing rate and reduces recurrence among patients with VLUs, but there is a need to assess the cost-effectiveness of early endovenous ablation in the US context.
View Article and Find Full Text PDFProvider imaging practices and outcomes of advanced colorectal cancer.
Cancer Treat Res Commun
September 2022
Purpose: To explore the real-world utilization of computerized tomography (CT) in patients with advanced colorectal cancer (CRC) and the associated outcomes.
Methods: Using Optum's de-identified Clinformatics® Data Mart Database (2008-2016), we identified patients with CRC receiving combination of chemotherapies (fluoropyrimidines with either oxaliplatin or irinotecan, or capecitabine with either oxaliplatin or irinotecan) combined with bevacizumab as the initial treatment, and its starting date was registered as the index date. End of treatment was defined by the presence of a gap in therapy > 60 days or treatment switch.
Objectives: This study aimed to assess the cost-effectiveness of fibrosis-based direct-acting antiviral treatment policies for patients with chronic hepatitis C virus at the Kaiser Permanente Mid-Atlantic States health system.
Methods: We used a Markov model to compare the lifetime costs and effects of treating patients with chronic hepatitis C virus at different stages of disease severity, or all stages simultaneously, based on a fibrosis score from the US healthcare sector perspective and societal perspective. The initial distribution of patients across fibrosis scores, the effectiveness of direct-acting antiviral therapy, and follow-up and monitoring protocols were specific to the Kaiser Permanente Mid-Atlantic States health system.
Background: The duration of extracorporeal membrane oxygenation (ECMO) has been historically confined in many centers to two weeks. We evaluated the cost-effectiveness of additional weeks on ECMO beyond two weeks for newborns with congenital diaphragmatic hernia (CDH) who may require longer stays to maximize survival potential.
Methods: We modeled lifetime outcomes using a decision tree from the US societal perspective.